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AbStRACt
Prostatic synovial sarcomas are exceedingly rare. To our knowledge, only six primary cases have 
been reported so far. We herein describe a primary synovial sarcoma of the prostate seen in a 25-
year-old male patient, the youngest patient seen with this disease to date. He was referred to our 
department with the diagnosis of high-grade sarcoma of the prostate revealed by TRUS-guided 
biopsy. On admission he had a transurethral catheter for acute retention of urine. MRI revealed 
a solid prostatic tumor of 9.5 x 8 cm involving the rectum without any evidence of lymphatic or 
distant metastases. The patient underwent total pelvic exenteration and sigmoid end colostomy 
with ileal conduit. Histopathology revealed a synovial sarcoma of the prostate, immunoreactive to 
vimentin, Bcl–2 and cytokeratin. The patient is doing well at 18 months follow-up. 
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INtRoDuCtIoN                                                    
Synovial sarcoma is a malignant mesen-
chymal tumor that typically arises in the pa-
ra-articular soft tissues of the lower extremi-
ties in young adults. The tumor is believed 
to arise from primitive mesenchymal cells 
that have differentiated to resemble synovial 
cells under light microscopy. Only 6 primary 
cases1-5 of synovial sarcoma of prostate have 
been reported in the literature. In view of its 
rarity and undefined management protocol 
we are reporting the youngest reported case 
to date.
CASe RePoRt                                      
A 25-year-old male patient was referred to 
our department from a secondary care center 
with the diagnosis of a high-grade sarcoma 
of the prostate diagnosed by transrectal ultra-
sound (TRUS)-guided biopsy. On admission 
he had a transurethral catheter for acute re-
tention of urine. He also had a foul-smelling 
mucoid and blood-stained discharge per rec-
tum. Rectal examination revealed grade-Ш 
prostatomegaly and a tumor involving the 
anterior rectal wall at the base and mid zone 
of the prostate. Histopathological review of 
the biopsy specimens confirmed the diagno-
sis. All hematological and biochemical inves-
tigations were normal. Serum PSA was 1.7 
ng/ml. Magnetic resonance imaging (MRI) of 
the abdomen and pelvis revealed a solid pros-
tatic tumor of 9.5 x 8 cm involving the rec-
tum, without significant lymphadenopathy or 
evidence of distant metastases (Fig. 1). The 
bone scan was normal. Urethroscopy revea-
led a shaggy and ulcerated prostatic urethra, 
completely invaded by the tumor. The blad-
der could not be entered. 
Surgical exploration was carried out via 
a midline incision. There was a large mass 
involving the prostate, bladder base and 
anterior wall of the rectum, extending to, but 
not invading the lateral pelvic walls. Only the 
most distal part of the rectum was tumor-free. 
A total pelvic exenteration with sigmoid end 
colostomy and ileal conduit was performed. 
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patients was 37–63 years1-5. We are reporting 
the youngest patient with locally advanced 
disease, lower abdominal and perineal pain 
and retention of urine. 
Sarcomas are radioresistant with poor 
response to chemotherapy. Hence, aggressive 
surgical treatment consisting of total pelvic 
exenteration with end sigmoid colostomy 
and ileal conduit was considered in view 
of the patient’s young age and the absence 
of lymph node involvement and distant 
metastases. Immunohistochemically proven 
bcl-2 positivity supported the diagnosis, 
because the anti-apoptotic protein bcl-2 
was recently reported to be well expressed 
in synovial sarcoma5,6. The tumor cells 
are also immunoreactive to vimentin and, 
focally, to cytokeratin. An immunostain for 
S100 and calponin was negative. Detecting 
the translocation t(X; 18) (p11.2; q11.2) 
and chimeric SYT-SSX gene by using 
fluorescence in situ hybridization or RT-PCR 
has been shown to be useful in diagnosing 
this disorder1,6,7.
In conclusion, due to the rarity of synovial 
sarcoma involving the prostate, no definitive 
treatment protocol has been clearly established. 
It appears that aggressive resection should be 
the rule. The documentation of further cases 
will be needed to establish the appropriate 
therapy.                         
Complete local clearance was achieved. 
The post-operative period was uneventful. 
The final histopathological examination 
revealed a synovial sarcoma of the prostate 
with surgical margins free of tumor (Fig. 2). 
On immunohistochemistry, the tumor cells 
were immunoreactive to vimentin, Bcl–2 
and focally for cytokeratin. Immunostaining 
for S100 and calponin was negative, which 
was compatible with synovial sarcoma of the 
prostate.
DISCuSSIoN                                                             
Synovial sarcoma accounts for 7-10% 
of all sarcomas1. Primary synovial sarcoma 
occurs in a variety of unusual locations, 
but rarely in the genitourinary system. 
Renal involvement has been reported 
more often, but prostate involvement is 
extremely unusual1,2. It arises from primitive 
mesenchymal cells which resemble synovial 
cells under light microscopy. The tumor is 
composed of two morphologically different 
types of cells, epithelial and spindle, and is 
classified as having a biphasic or monophasic 
pattern, depending on the proportions of 
these cells. As compared with the most 
common malignant tumor of the prostate, 
adenocarcinoma, prostatic sarcoma occurs 
in relatively younger patients. According to 
previous reports, the age at diagnosis of these 
Fig. 1: MRI of the abdomen and pelvis showing a solid 
prostatic tumor with central necrosis involving the rectum and 
pushing the bladder anteriorly and superiorly.
Fig. 2:  Histopathology study of the specimen (HE x 400). 
The tumor was mainly composed of uniform spindle cells with 
cellular atypia and few interposed immature epithelioid cells.
185
A RARe CAse of syNoViAl sARComA of the PRostAte
ReFeReNCeS                                                        
Iwasaki H, Ishiguro M, Ohjimi Y, Ikegami H, Takeuchi 1. 
T, Kikuchi M, et al. Synovial sarcoma of the prostate 
with t(X;18)(p11.2;q11.2). Am.J.Surg.Pathol. 1999; 
Feb;23(2):220-6.
Shirakawa T, Fujisawa M, Gotoh A, Okada H, Arakawa 2. 
S, Kamidono S. Complete resection of synovial sarcoma 
of prostatic fascia. Urology. 2003; Mar;61(3):644.
Williams DH, Hua VN, Chowdhry AA, Laskin WB, 3. 
Kalapurakal JA, Dumanian GA, et al. Synovial sarcoma 
of the prostate. J.Urol. 2004; Jun;171(6 Pt 1):2376.
Pan CC, Chang YH. Primary synovial sarcoma of the 4. 
prostate. Histopathology. 2006; Feb;48(3):321-3.
Jun L, Ke S, Zhaoming W, Linjie X, Xinru Y. Primary 5. 
synovial sarcoma of the prostate: Report of 2 cases and 
literature review. Int.J.Surg.Pathol. 2008; Jul;16(3):329-
34.
Antonescu CR, Kawai A, Leung DH, Lonardo F, 6. 
Woodruff JM, Healey JH, et al. Strong association 
of SYT-SSX fusion type and morphologic epithelial 
differentiation in synovial sarcoma. Diagn.Mol.Pathol. 
2000; Mar;9(1):1-8.
Lubieniecka JM, de Bruijn DR, Su L, van Dijk 7. 
AH, Subramanian S, van de Rijn M, et al. Histone 
deacetylase inhibitors reverse SS18-SSX-mediated 
polycomb silencing of the tumor suppressor early growth 
response 1 in synovial sarcoma. Cancer Res. 2008; Jun 
1;68(11):4303-10.
